Coeptis Reconciled Depreciation from 2010 to 2024
| COEP Stock | USD 0.20 0.01 5.26% |
Reconciled Depreciation | First Reported 2010-12-31 | Previous Quarter 1 M | Current Value 762.7 K | Quarterly Volatility 251 K |
Check Coeptis Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Coeptis Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 616.3 K, Other Operating Expenses of 41.3 M or Total Operating Expenses of 41.3 M, as well as many indicators such as Price To Sales Ratio of 5.2 K, Dividend Yield of 0.0 or PTB Ratio of 4.43. Coeptis financial statements analysis is a perfect complement when working with Coeptis Therapeutics Valuation or Volatility modules.
Coeptis | Reconciled Depreciation |
Latest Coeptis Therapeutics' Reconciled Depreciation Growth Pattern
Below is the plot of the Reconciled Depreciation of Coeptis Therapeutics over the last few years. It is Coeptis Therapeutics' Reconciled Depreciation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Coeptis Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Reconciled Depreciation | 10 Years Trend |
|
Reconciled Depreciation |
| Timeline |
Coeptis Reconciled Depreciation Regression Statistics
| Arithmetic Mean | 451,366 | |
| Geometric Mean | 406,866 | |
| Coefficient Of Variation | 55.61 | |
| Mean Deviation | 188,170 | |
| Median | 323,428 | |
| Standard Deviation | 250,987 | |
| Sample Variance | 63B | |
| Range | 678K | |
| R-Value | 0.70 | |
| Mean Square Error | 34.4B | |
| R-Squared | 0.49 | |
| Significance | 0 | |
| Slope | 39,385 | |
| Total Sum of Squares | 881.9B |
Coeptis Reconciled Depreciation History
About Coeptis Therapeutics Financial Statements
Coeptis Therapeutics shareholders use historical fundamental indicators, such as Reconciled Depreciation, to determine how well the company is positioned to perform in the future. Although Coeptis Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Coeptis Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Coeptis Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Reconciled Depreciation | 1 M | 762.7 K |
Pair Trading with Coeptis Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Coeptis Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Coeptis Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Coeptis Stock
| 0.57 | HLN | Haleon plc | PairCorr |
| 0.55 | ELAN | Elanco Animal Health | PairCorr |
| 0.51 | ZTS | Zoetis Inc | PairCorr |
| 0.44 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.41 | TAK | Takeda Pharmaceutical | PairCorr |
The ability to find closely correlated positions to Coeptis Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Coeptis Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Coeptis Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Coeptis Therapeutics to buy it.
The correlation of Coeptis Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Coeptis Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Coeptis Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Coeptis Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Coeptis Stock Analysis
When running Coeptis Therapeutics' price analysis, check to measure Coeptis Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coeptis Therapeutics is operating at the current time. Most of Coeptis Therapeutics' value examination focuses on studying past and present price action to predict the probability of Coeptis Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coeptis Therapeutics' price. Additionally, you may evaluate how the addition of Coeptis Therapeutics to your portfolios can decrease your overall portfolio volatility.